Vertex Pharmaceuticals Incorporated: Business Overview, Financials & Competitive Analysis
Vertex Pharmaceuticals Incorporated scores 8/10 on the AskCyborg Cyborg Score (Strong). Vertex has intellectual property to secure CF leadership through the late 2030s while executing multi-billion dollar expansion into gene editing and specialty medicines. Vertex has demonstrated steady gains with a 90 day share price return of 6.38% and a five year total shareholder return of 121.62%, backed by dominant.
What is Vertex Pharmaceuticals Incorporated's industry? Vertex Pharmaceuticals Incorporated (vrtx.com) operates in Biopharmaceuticals & Specialty Pharma. AskCyborg classifies Vertex Pharmaceuticals Incorporated under Biopharmaceuticals & Specialty Pharma in its company registry.
Vertex Pharmaceuticals, founded in 1989 and headquartered in Boston, Massachusetts, is a global biotechnology company specializing in transformative medicines for serious diseases. The company reported 2025 revenue of...
Cyborg Score thesis
Vertex has intellectual property to secure CF leadership through the late 2030s while executing multi-billion dollar expansion...
Read the full analyst-debate transcript →Get the Latest Vertex Pharmaceuticals Incorporated Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeVertex Pharmaceuticals Incorporated Overview
Pro stress-test →Vertex Pharmaceuticals, founded in 1989 and headquartered in Boston, Massachusetts, is a global biotechnology company specializing in transformative medicines for serious diseases. The company reported 2025 revenue of $12.0 billion with 9% growth, and 2026 guidance of up to $13.1 billion, with at least $500 million expected from non-CF drugs CASGEVY and JOURNAVX.
Strategic Profile
Pro stress-test →Vertex has secured leadership in cystic fibrosis (CF), where CFTR modulators can treat nearly 95 percent of all people living with CF in core markets. The company has proven it can expand into other treatment areas, winning approval for gene editing treatment Casgevy for blood disorders and Journavx, a non-opioid drug for pain management.
Competitive Landscape
Pro stress-test →Vertex dominates cystic fibrosis with secured market leadership. In emerging areas, it competes with broader biotech/pharma companies including Roche, Novartis, Regeneron, and others in gene therapy, kidney disease, and pain management segments. Competition intensifies as pipeline products progress through clinical development.
Industry Context
Vertex Pharmaceuticals Incorporated operates in Biopharmaceuticals & Specialty Pharma.
Key facts
Founded: 1989 · Headquarters: Boston, US · Revenue: $12.0B · Market cap: $118B